...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: BIO-Europe Presentation
5
Mar 13, 2018 12:09PM
6
Mar 13, 2018 04:05PM
3
Mar 14, 2018 10:35AM

"3) Phase 1b/2a: ZEN-3694 + PARPi in HRD+/ HRD- patients (breast, CRPC, ovarian), DE and DC. I did not know what all of these acronyms mean, but this helps. I still don't know what DE and DC are."

I asked Clayton and he clarified: "DE = Dose Escalation; DC = Dose Confirmation"

Share
New Message
Please login to post a reply